ENDOCRINE SIDE EFFECTS OF ANTI-CANCER DRUGS: Effects of anti-cancer targeted therapies on lipid and glucose metabolism
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
ENDOCRINE SIDE EFFECTS OF ANTI-CANCER DRUGS: Effects of anti-cancer targeted therapies on lipid and glucose metabolism
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF ENDOCRINOLOGY
Volume 170, Issue 2, Pages R43-R55
Publisher
Bioscientifica
Online
2013-10-24
DOI
10.1530/eje-13-0586
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Duration of Rapamycin Treatment Has Differential Effects on Metabolism in Mice
- (2013) Yimin Fang et al. Cell Metabolism
- Efficacy of everolimus in patients with metastatic insulinoma and refractory hypoglycemia
- (2013) Valérie Bernard et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib
- (2012) P. Reichardt et al. ANNALS OF ONCOLOGY
- mTOR Signaling in Growth Control and Disease
- (2012) Mathieu Laplante et al. CELL
- Mechanistic target of rapamycin inhibitors in solid organ transplantation
- (2012) Maxime Touzot et al. Current Opinion in Organ Transplantation
- Impact of Sunitinib Treatment on Blood Glucose Levels in Patients with Metastatic Renal Cell Carcinoma
- (2012) J. J. Oh et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Regulation of hepatic LDL receptors by mTORC1 and PCSK9 in mice
- (2012) Ding Ai et al. JOURNAL OF CLINICAL INVESTIGATION
- Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway
- (2012) Naifa L. Busaidy et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
- (2012) Antonio C. Wolff et al. JOURNAL OF CLINICAL ONCOLOGY
- Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
- (2012) Winette TA van der Graaf et al. LANCET
- Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial
- (2012) David Neal Franz et al. LANCET
- mTOR inhibition with rapamycin causes impaired insulin signalling and glucose uptake in human subcutaneous and omental adipocytes
- (2012) Maria J. Pereira et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity
- (2012) D. W. Lamming et al. SCIENCE
- Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML
- (2011) Karl J. Aichberger et al. AMERICAN JOURNAL OF HEMATOLOGY
- mTOR Complex 1 Regulates Lipin 1 Localization to Control the SREBP Pathway
- (2011) Timothy R. Peterson et al. CELL
- Second line BCR/ABK TKI-associated severe adverse events:preferential occurrence in patients with comorbidities
- (2011) P. Valent HAEMATOLOGICA
- Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
- (2011) Marianne E Pavel et al. LANCET
- Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
- (2011) Eric Raymond et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus for Advanced Pancreatic Neuroendocrine Tumors
- (2011) James C. Yao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lipid Profile Changes During the First Year After Kidney Transplantation: Risk Factors and Influence of the Immunosuppressive Drug Regimen
- (2011) G.A. Spinelli et al. TRANSPLANTATION PROCEEDINGS
- Efficacy and Safety of Sirolimus and Everolimus in Heart Transplant Patients: A Retrospective Analysis
- (2011) B. Baur et al. TRANSPLANTATION PROCEEDINGS
- Chronic Rapamycin Treatment Causes Glucose Intolerance and Hyperlipidemia by Upregulating Hepatic Gluconeogenesis and Impairing Lipid Deposition in Adipose Tissue
- (2010) V. P. Houde et al. DIABETES
- Endocrine side effects of broad-acting kinase inhibitors
- (2010) Maya B Lodish et al. ENDOCRINE-RELATED CANCER
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- mTORC1 controls fasting-induced ketogenesis and its modulation by ageing
- (2010) Shomit Sengupta et al. NATURE
- Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
- (2010) Giuseppe Saglio et al. NEW ENGLAND JOURNAL OF MEDICINE
- Management of Side Effects of Sirolimus Therapy
- (2010) Giovanni Stallone et al. TRANSPLANTATION
- AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity
- (2009) C. M. Chresta et al. CANCER RESEARCH
- ULK1·ATG13·FIP200 Complex Mediates mTOR Signaling and Is Essential for Autophagy
- (2009) Ian G. Ganley et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
- (2009) Georg Hess et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
- (2009) Ronald P DeMatteo et al. LANCET
- Molecular mechanisms of mTOR-mediated translational control
- (2009) Xiaoju Max Ma et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Glycemic Control in Patients with Insulinoma Treated with Everolimus
- (2009) Matthew H. Kulke et al. NEW ENGLAND JOURNAL OF MEDICINE
- Insulin Stimulates Adipogenesis through the Akt-TSC2-mTORC1 Pathway
- (2009) Hui H. Zhang et al. PLoS One
- Mammalian Target of Rapamycin Inhibitor Dyslipidemia in Kidney Transplant Recipients
- (2008) B. L. Kasiske et al. AMERICAN JOURNAL OF TRANSPLANTATION
- mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1)
- (2008) Juan M. García-Martínez et al. BIOCHEMICAL JOURNAL
- Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib
- (2008) B Billemont et al. BRITISH JOURNAL OF CANCER
- SREBP Activity Is Regulated by mTORC1 and Contributes to Akt-Dependent Cell Growth
- (2008) Thomas Porstmann et al. Cell Metabolism
- Regulation of Ceramide Biosynthesis by TOR Complex 2
- (2008) Sofia Aronova et al. Cell Metabolism
- Skeletal Muscle-Specific Ablation of raptor, but Not of rictor, Causes Metabolic Changes and Results in Muscle Dystrophy
- (2008) C. Florian Bentzinger et al. Cell Metabolism
- mTOR Inhibition by Rapamycin Prevents -Cell Adaptation to Hyperglycemia and Exacerbates the Metabolic State in Type 2 Diabetes
- (2008) M. Fraenkel et al. DIABETES
- Sirolimus Is Associated with New-Onset Diabetes in Kidney Transplant Recipients
- (2008) O. Johnston et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
- Biphasic Response of Pancreatic -Cell Mass to Ablation of Tuberous Sclerosis Complex 2 in Mice
- (2008) Y. Shigeyama et al. MOLECULAR AND CELLULAR BIOLOGY
- Disruption of Tsc2 in pancreatic cells induces cell mass expansion and improved glucose tolerance in a TORC1-dependent manner
- (2008) L. Rachdi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PCSK9 and LDL cholesterol: unravelling the target to design the bullet
- (2008) Philippe Costet et al. TRENDS IN BIOCHEMICAL SCIENCES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started